Interaction Guide · Research summary

Can I take Piper Methysticum with Clonazepam?

Review Piper Methysticum with Clonazepam: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Avoid adding kava to clonazepam without prescriber review. Official kava guidance advises against combining it with sedating substances.

What this answer covers

Oral Piper methysticum; extract, dose and other sedatives must be identified.

Supplement or preparation
Piper methysticum
Medication ingredient
clonazepam

Why the precaution applies

NCCIH advises against combining kava with sedatives. Clonazepam can impair alertness and coordination, making this a relevant precaution even without a measured combination risk.

Separate treatments are not a safety test

A small driving study tested kava, oxazepam and placebo on separate occasions. Kava did not impair the tested driving outcomes, but the study did not combine the products or use this medication.

Spacing has not been validated

Bring the kava extract, amount and frequency to the prescriber. Taking the products a few hours apart has not been shown to prevent combined impairment.

Watch for impaired alertness

Clonazepam can affect alertness and coordination. Avoid driving if affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about alcohol, opioids and all other sedating products.

Evidence and practical considerations

Side effects & toxicity

Conditional avoid/review precaution follows kava guidance and the exact medication CNS effects; no measured exact-pair risk magnitude.

Exact scope
Oral Piper methysticum; extract, dose and other sedatives must be identified. with Exact oral clonazepam tablets. CYP3A may participate in reduction and oxidation; named enzyme-inducing anticonvulsants lower levels. REM sleep behavior disorder is a separate, off-label study population, not the labeled panic/seizure indication.
Medication form and route
oral
Timing or duration
Source-specific single-dose, repeated-dose and observational exposures distinguished.

What remains uncertain

  • A separate-dose oxazepam comparison is not a combination study. No exact protective spacing interval or universally safe kava dose.

Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.

Research conclusion: supported with conditions · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed oral clonazepam.

Can impair alertness and coordination; other CNS depressants can increase impairment. Opioid combinations have a specific respiratory-depression warning. Dependence and withdrawal require supervised changes. CYP3A may participate in reduction and oxidation; named enzyme-inducing anticonvulsants lower levels. REM sleep behavior disorder is a separate, off-label study population, not the labeled panic/seizure indication.

How this applies: Exact IN and labeled oral formulation; route, salt and metabolite distinctions retained.

No quantified risk for every herb or universal protective spacing interval. Opioid-specific evidence does not prove equal botanical respiratory risk.

Source 2: official guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the specified supplement.

Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.

How this applies: Preparation-specific context; not a directly measured clonazepam interaction.

Not a clonazepam study. Intrinsic liver risk does not establish added clonazepam hepatotoxicity; preparation and co-exposure vary.

Source 3: original human study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Twenty-two adults in a randomized crossover driving study.

Medicinal-dose kava did not significantly impair driving outcomes; oxazepam impaired some outcomes.

How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.

Not combined administration or evidence that all kava preparations lack impairment.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Current exact available claims adjudicated using original captures and explicit identity and comparator limits.
Research summary published

Article revision: ceb52bf1a1e8e2d8

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.